Putney Hires Catherine Conaty as VP of Finance & Controller

Portland, ME—December 10, 2014—Putney, Inc., a rapidly growing pharmaceutical company focused on the development and sale of generic prescription medicines for pets, has hired Catherine Conaty as Vice President of Finance & Controller, reporting to Putney CFO, William McKee. Conaty joins Putney's senior management team to lead the finance department and implement efficient systems and processes to support Putney's commercial growth in 2015 and beyond. In addition to her financial responsibilities, she will oversee Putney's IT department and the continuing implementation of a cloud-based ERP system, the first phase of which has already been successfully completed across the company's finance department.

Conaty has over thirty years of financial management experience, most recently with a series of early stage technology and pharmaceutical companies where she was instrumental in building the financial systems and reporting infrastructure to support high growth following new product launches. Her expertise in working with companies that are scaling operations rapidly includes overseeing a 5X jump in annual revenue at a medical device company that was later acquired by Johnson & Johnson.

Jean Hoffman, president and CEO of Putney, says Conaty's experience will help Putney meet its aggressive growth goals. "Putney is the first generic company dedicated to the companion animal market. As we deliver new generic options from our pipeline this year, we are putting the people and systems in place to manage our expanding operations," says Hoffman.

 

About Putney

Putney is a pharmaceutical company committed to providing high quality, cost-effective generic medicines for pets. Putney's reliable supply of affordable drug options empowers veterinarians, allowing them to provide the best possible medicine at the best possible price, and supports pet owners, helping them afford to comply with veterinary recommendations. Putney's ongoing investment in research and development is focused on creating the next generation of generic veterinary products based on inputs from companion animal veterinarians and its industry partners. Learn more at www.putneyvet.com.

Suggested Articles

Pfizer spinoff Zoetis met Q2 expectations and brightened its full-year forecast, but it's looking to M&A to drive further growth.

Fresenius’ new CEO has pulled off a dealmaking double play, committing more than $5.4 billion to expand its reach in both sterile generics and in biosimilars.

Bayer’s pharma products have been growing lickety-split, and its 2016 numbers show just how—and how much. But with the big Monsanto merger top of mind at Bayer…